← Back to headlines
Neurocrine Biosciences Raises INGREZZA Sales Guidance
Neurocrine Biosciences has increased its 2026 sales guidance for its drug INGREZZA to $2.825B-$2.875B, while also integrating VYKAT XR.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
